News >

TKI/Immunotherapy Combos Lead Advances in mRCC, But Questions Remain

Brittany Cote
Published: Wednesday, Mar 11, 2020

Chung-Han Lee, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center

Chung-Han Lee, MD, PhD

Three immunotherapy combinations have transformed first-line treatment for patients with metastatic renal cell carcinoma (mRCC), yet questions remain on what the optimal strategy is for patients who progress on these regimens, explained Chung-Han (Joe) Lee, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication